Efficacy of neoadjuvant chemoimmunotherapy in locally advanced resectable esophageal cancer
NICT significantly improves pathological response and survival rates in patients with locally advanced resectable ESCC, with a favorable safety profile. These findings highlight the potential of NICT to transform the treatment landscape of ESCC. Future research should focus on the optimizing treatment regimens, identifying predictive biomarkers, and reducing toxicity to improve clinical outcomes and achieve personalized treatment.
Authors
- Hongmei Zhang (ORCID: https://orcid.org/0000-0002-6421-4126)
- Lingshuo Kong
- Ruidan Zhang (ORCID: https://orcid.org/0000-0002-4924-8766)
- Bin Zhang (ORCID: https://orcid.org/0000-0001-9398-6814)
- Xinwei Li (ORCID: https://orcid.org/0000-0002-9842-5546)
- Yan Yi (ORCID: https://orcid.org/0000-0002-1632-7329)
- Baosheng Li (ORCID: https://orcid.org/0000-0002-5390-7269)
- Qiang Cao (ORCID: https://orcid.org/0000-0001-8160-8883)
Institutions
- Shandong Tumor Hospital (CN)
- Linyi City Chinese Medicine Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Journal of Cancer Research and Therapeutics
- Published
- 2025-09-01
- DOI
- https://doi.org/10.4103/jcrt.jcrt_583_25
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00